|Back Zoom + Zoom -|
The offer prices of Shanghai Henlius Biotech (02696.HK), a spin-off of FOSUN PHARMA (02196.HK), range $49.6-57.8; entry fee is $5,838.25 per board lot of 100 shares, according to filings seen by our reporters.
The biotech firm, to be listed on 25 September, plans to raise US$409-477 million and has Qatar Investment Authority as one of its cornerstone investors, who made US$90-million subscription, said the document.
AAStocks Financial News
Web Site: www.aastocks.com